Bijoy Hans Peer Comparison

BSE: 524723

₹98.85

₹-2.00 (-1.98%)

As on 16-Oct-2026IST

Market cap

₹475 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

8.3

Div. Yield

0 %

Edit

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	475	31,674	26,307	26,224	25,017
Revenue (₹ Cr)	0	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	-1.99	414.00	-371.81	387.35	288.22
Net Margin (%)	-668.12	11.23	-3.93	26.01	14.79
RoE (%)	-5.98	8.38	-3.85	25.18	29.77
Price to Earnings	--	77.44	--	67.90	86.80
Price-To-Book	8.31	6.29	3.29	15.20	18.64

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	0.10	3,564.00	9,205.28	1,461.80	1,935.80
Total Income	0.30	3,686.00	9,449.59	1,489.25	1,948.58
Total Expenditure	2.14	2,792.00	8,195.15	919.25	1,485.56
EBITDA	-2.04	772.00	1,010.13	542.56	450.24
Depreciation	0.00	226.00	857.51	37.68	50.83
EBIT	-2.04	546.00	152.62	504.88	399.41
Interest	0.15	217.00	342.73	3.77	40.84
Other Income	0.20	122.00	244.31	27.45	12.78
Exceptional Items	0.00	12.00	-216.88	0.00	0.00
Profit before Tax	-1.99	463.00	-162.68	528.56	371.35
Provision for Tax	0.00	49.00	209.13	141.21	83.14
Profit after Tax	-1.99	414.00	-371.81	387.35	288.22

Liabilities (₹ Cr)

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	58.00	4,940.00	8,162.62	1,653.56	1,288.82
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	0.00	1,712.00	5,044.14	42.40	202.03
Current Liabilities	10.38	1,622.00	4,758.28	230.82	835.87
Total Liabilities	3.59	8,100.00	15,513.53	1,549.26	1,451.43

Assets (₹ Cr)

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	60.78	5,343.00	10,211.52	1,026.85	519.60
Current Assets	7.59	2,606.00	7,191.66	881.27	1,681.81
Total Assets	3.59	8,100.00	15,513.53	1,549.26	1,451.43
Total Debt*	0.00	1,859.00	4,720.27	8.18	393.17
Net Current Assets	-2.79	984.00	2,433.38	650.46	845.94
Contingent Liabilities	--	770.26	99.76	15.38	12.25

Cashflow (₹ Cr)

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	0.22	-22.00	892.30	118.34	159.18
Cash Flow from Investing Activities	0.92	-783.00	-477.46	-223.94	-64.81
Cash from Financing Activities	-0.06	409.00	-440.83	261.12	-39.81
Net Cash Inflow / Outflow	1.08	-396.00	-25.99	155.52	54.56

Ratios

Profitability Ratios

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	5.74	4.07	6.61	20.14	26.97
ROE (%)	-5.98	8.38	-3.85	25.18	29.77
ROA (%)	-5.53	4.94	-2.21	21.93	24.77
EBIT Margin (%)	-2,043.00	15.32	1.66	34.54	20.63
Net Margin (%)	-668.12	11.23	-3.93	26.01	14.79
Cash Profit Margin (%)	57.56	0.00	0.00	0.00	0.00

Growth Ratios

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	-48.19	18.37	0.78	40.90	46.65
EBIT Growth (%)	-182.18	252.26	-70.53	124.50	62.13
Net Profit Growth (%)	-3,010.94	377.85	-1,383.43	104.15	89.49
EPS Growth (%)	39.91	1,001.33	-484.84	42.32	78.60
Book Value Growth (%)	4.01	29.77	2.28	94.96	42.49

Valuation Ratios

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	-104.66	79.49	-84.07	67.90	85.46
Price / Book Value	8.31	6.29	3.29	15.20	18.64
Dividend Yield (%)	0.00	0.00	0.00	0.08	0.10
EV/EBITDA	-231.03	42.92	30.14	47.97	55.37
Market Cap (₹ Cr)	0.00	23,064.69	29,731.27	19,988.69	0.00

Solvency Ratios

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.00	0.31	0.53	0.01	0.11
Short term debt to equity ratio	--	0.11	0.12	0.02	0.54
Current Ratio	0.73	1.61	1.51	3.82	2.01
Quick Ratio	0.73	1.06	0.87	2.82	1.14
Interest Coverage	-12.64	3.13	0.53	141.16	10.09

Operating Efficiency Ratios

	Bijoy Hans	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	0.00	16.50	23.44	24.80	26.28
Asset Turnover	0.00	0.43	0.55	0.83	1.66
Receivable days	0.00	60.36	77.05	90.06	47.59
Inventory Days	0.00	64.42	77.13	61.02	62.58
Payable days	--	218.94	173.49	96.06	228.78
Cash Conversion Cycle	--	-94.15	-19.30	55.02	-118.62

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.